Georgia

Psychedelic trials in Georgia

47 registered trials has a study site in Georgia, and 8 are recruiting now.

Trials with a site here

Recruiting

Facilities

Open now

Recruiting in this state

Trial	Status	Phase	Substance	Sites
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL Limited	Recruiting	Phase 3	psilocybin	68
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)NCT07592689 · Definium Therapeutics US, Inc.	Recruiting	Phase 3	lsd	30
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence StudyNCT06713616 · Yale University	Recruiting	Phase 3	ketamine	8
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderNCT07227454 · Janssen Research & Development, LLC	Recruiting	Phase 3	ketamine	35
MDMA-Assisted Massed Exposure Therapy for PTSDNCT07288151 · Emory University	Recruiting	Phase 2	mdma	1
Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsNCT07516405 · University of Colorado, Denver	Recruiting	Phase 1	psilocybin	6
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With KetamineNCT05327699 · Emory University	Recruiting	Early Phase 1	ketamine	1
The OBSERVE ProtocolNCT06725277 · Yale University	Recruiting	N/A	ketamine	8

Facilities

Where the research happens in Georgia

Facility	City	Trials
Emory University	Atlanta	9
iResearch Atlanta	Decatur	5
Atlanta Center for Medical Research	Atlanta	4
Psych Atlanta	Marietta	3
Atlanta Behavioral Research, LLC	Atlanta	3
Emory Brain Health Center	Atlanta	2
CenExel iResearch, LLC	Decatur	2
CenExel ACMR	Atlanta	2
Seelos Investigational Site	Atlanta	2
Mood and Anxiety Disorders Program Emory University School of Medicine	Atlanta	2
Emory University Dept of Psychiatry and Behavioral Studies	Atlanta	1
CenExel - Atlanta Center for Medical Research	Atlanta	1
CenExel - iResearch Atlanta	Decatur	1
CenExel - iResearch Savannah	Savannah	1
Peachford Hospital-Atlanta Behavioral Research	Atlanta	1
Emory University Brain Health Center	Atlanta	1
Psych Atlanta, P.C.	Marietta	1
Atlanta Centre	Atlanta	1
Atlanta VA Medical and Rehab Center, Decatur, GA	Decatur	1
Atlanta Center for Medical Research, CenExel	Atlanta	1
CenExel iResearch Atlanta	Decatur	1
CenExel iResearch Savannah	Savannah	1
Clinical Site 118	Atlanta	1
Clinical Site 138	Marietta	1
Clinical Site 114	Savannah	1
Emory University Hospital	Atlanta	1
Advanced Discovery Research	Atlanta	1
Clinical Site 140	Atlanta	1
Clinical Site 104	Decatur	1
Clinical Site 122	Marietta	1
Novartis Investigative Site	Atlanta	1
Emory University/Winship Cancer Institute	Atlanta	1
Brain Health Center at Executive Park	Atlanta	1
PsychAtlanta	Marietta	1

Stay told

When a trial opens in Georgia

All trials

Every trial with a Georgia site

Trial	Status	Phase	Substance	Sites
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL Limited	Recruiting	Phase 3	psilocybin	68
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)NCT07592689 · Definium Therapeutics US, Inc.	Recruiting	Phase 3	lsd	30
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence StudyNCT06713616 · Yale University	Recruiting	Phase 3	ketamine	8
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderNCT07227454 · Janssen Research & Development, LLC	Recruiting	Phase 3	ketamine	35
MDMA-Assisted Massed Exposure Therapy for PTSDNCT07288151 · Emory University	Recruiting	Phase 2	mdma	1
Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsNCT07516405 · University of Colorado, Denver	Recruiting	Phase 1	psilocybin	6
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With KetamineNCT05327699 · Emory University	Recruiting	Early Phase 1	ketamine	1
The OBSERVE ProtocolNCT06725277 · Yale University	Recruiting	N/A	ketamine	8
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant DepressionNCT04599855 · Janssen Research & Development, LLC	Completed	Phase 4	ketamine	54
A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental HealthNCT05604794 · Field Trip Health	Completed	Phase 4	ketamine	11
VA Aripiprazole vs Esketamine for Treatment Resistant DepressionNCT05554627 · VA Office of Research and Development	Withdrawn	Phase 4	ketamine	26
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"NCT06564818 · Cybin IRL Limited	Active, not recruiting	Phase 3	psilocybin	45
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDNCT05624268 · COMPASS Pathways	Completed	Phase 3	psilocybin	40
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDNCT05711940 · COMPASS Pathways	Active, not recruiting	Phase 3	psilocybin	116
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)NCT06809595 · Definium Therapeutics US, Inc.	Active, not recruiting	Phase 3	lsd	36
Psilocybin for Major Depressive Disorder (MDD)NCT06308653 · Usona Institute	Active, not recruiting	Phase 3	psilocybin	29
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)NCT06741228 · Definium Therapeutics US, Inc.	Active, not recruiting	Phase 3	lsd	34
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT02418585 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	48
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant DepressionNCT02422186 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	69
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant DepressionNCT02493868 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	155
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant DepressionNCT02497287 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	109
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant DepressionNCT02782104 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	173
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03097133 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	61
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT03434041 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	30
Electrophysiologic Mechanisms of Ketamine Antidepressant ResponseNCT07768618 · Emory University	Not yet recruiting	Phase 2	ketamine	1
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)NCT06051721 · Cybin IRL Limited	Completed	Phase 2	dmt	6
MDMA Plus Exposure Therapy for PTSDNCT05746572 · Emory University	Enrolling by invitation	Phase 2	mdma	1
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive DisorderNCT06340958 · Clexio Biosciences Ltd.	Completed	Phase 2	ketamine	23
Psilocybin-Assisted TherapyNCT07332143 · Emory University	Not yet recruiting	Phase 2	psilocybin	1
Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002NCT06816433 · Global Coalition for Adaptive Research	Suspended	Phase 2	ketamine	9
A Study of Psilocybin for Major Depressive Disorder (MDD)NCT03866174 · Usona Institute	Completed	Phase 2	psilocybin	11
A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety SymptomsNCT05407064 · Definium Therapeutics US, Inc.	Completed	Phase 2	lsd	22
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO StudyNCT04103892 · Clexio Biosciences Ltd.	Completed	Phase 2	ketamine	46
A Study of Ketamine in Patients With Treatment-resistant DepressionNCT01627782 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	13
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant DepressionNCT01998958 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	25
A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for SuicideNCT02133001 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	14
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for SuicideNCT03185819 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	51
A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRDNCT05414422 · Perception Neuroscience	Completed	Phase 2	ketamine	21
A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive DisorderNCT05385783 · Cybin IRL Limited	Completed	Phase 1 / Phase 2	psilocybin	3
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of SuicideNCT04669665 · Seelos Therapeutics, Inc.	Completed	Phase 2	ketamine	21
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionNCT03775200 · COMPASS Pathways	Completed	Phase 2	psilocybin	25
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant DepressionNCT03756129 · Novartis Pharmaceuticals	Completed	Phase 2	ketamine	12
Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic PainNCT05506982 · Emory University	Completed	Phase 1	psilocybin	2
Evaluation of MDMA on Startle ResponseNCT03181763 · Resilient Pharmaceuticals	Completed	Phase 1	mdma	1
Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse PreventionNCT04760652 · Yale University	Completed	Not applicable	ketamine	3
Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)NCT04519957 · COMPASS Pathways	Completed	N/A	psilocybin	8
Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic KetamineNCT04856124 · Psych Atlanta	Completed	N/A	ketamine	1

Site locations from ClinicalTrials.gov API v2, data build 2026-08-25.

Elsewhere